TOKYO -- Takeda Pharmaceutical's ambitious goal to increase sales to 5 trillion yen ($46 billion) in a decade was met with apathy from investors, underscoring the lack of returns from recent big-ticket acquisitions.
The Japanese drugmaker's stock has edged 2% lower since Dec. 9, when President and CEO Christophe Weber disclosed the sales goal to analysts, saying it can be achieved by fiscal 2030 -- the first concrete long-term target since the company's 2019 acquisition of Irish counterpart Shire for $62 billion.
